Neurocrine Biosciences (NBIX) Leases (2019 - 2026)

Neurocrine Biosciences' Leases history runs 8 years deep, the most recent figure standing at $447.1 million for Q1 2026.

• Quarterly Leases fell 10.97% year-over-year to $447.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447.1 million (down 10.97% YoY) and the FY2025 annual result came in at $455.4 million, down 10.6% from the prior year.
• Leases was $447.1 million for Q1 2026 at Neurocrine Biosciences, down from $455.4 million in the prior quarter.
• Across five years, Leases topped out at $509.4 million in Q4 2024 and bottomed at $80.8 million in Q3 2023.
• A 5-year average of $263.4 million and a median of $257.3 million in 2024 frame the typical range for Leases.
• Annual changes were most pronounced in 2024 — Leases surged 220.85% — and 2026, when it retreated 10.97%.
• Neurocrine Biosciences' Leases stood at $87.0 million in 2022, then surged by 128.74% to $199.0 million in 2023, then soared by 155.98% to $509.4 million in 2024, then retreated by 10.6% to $455.4 million in 2025, then dropped by 1.82% to $447.1 million in 2026.
• Business Quant data shows NBIX's Leases at $447.1 million in Q1 2026, $455.4 million in Q4 2025, and $468.9 million in Q3 2025.